Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Neoplasms of the CNS

  Free Subscription

Articles published in Cancer

Retrieve available abstracts of 94 articles:
HTML format

Single Articles

    March 2021
  1. HANANIA AN, Paulino AC, Ludmir EB, Shah VS, et al
    Early radiotherapy preserves vision in sporadic optic pathway glioma.
    Cancer. 2021 Mar 19. doi: 10.1002/cncr.33497.
    PubMed     Abstract available

  2. NANTAVITHYA C, Paulino AC, Liao K, Woodhouse KD, et al
    Observed-to-expected incidence ratios of second malignant neoplasms after radiation therapy for medulloblastoma: A surveillance, epidemiology, and end results analysis.
    Cancer. 2021 Mar 15. doi: 10.1002/cncr.33507.
    PubMed     Abstract available

  3. BANDER ED, Yuan M, Carnevale JA, Reiner AS, et al
    Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies.
    Cancer. 2021 Mar 2. doi: 10.1002/cncr.33459.
    PubMed     Abstract available

    January 2021
  4. REARDON DA, Kim TM, Frenel JS, Simonelli M, et al
    Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial.
    Cancer. 2021 Jan 26. doi: 10.1002/cncr.33378.
    PubMed     Abstract available

    September 2020
  5. QIAN JM, Martin AM, Martin K, Hammoudeh L, et al
    Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases.
    Cancer. 2020 Sep 14. doi: 10.1002/cncr.33196.
    PubMed     Abstract available

    July 2020
  6. STEINDL A, Yadavalli S, Gruber KA, Seiwald M, et al
    Neurological symptom burden impacts survival prognosis in patients with newly diagnosed non-small cell lung cancer brain metastases.
    Cancer. 2020 Jul 17. doi: 10.1002/cncr.33085.
    PubMed     Abstract available

    June 2020
    Pathfinders in oncology from the beginning of modern surgery of intracranial tumors to the introduction of the Pap smear.
    Cancer. 2020;126:2734-2749.
    PubMed     Abstract available

  8. KARSCHNIA P, Batchelor TT, Jordan JT, Shaw B, et al
    Primary dural lymphomas: Clinical presentation, management, and outcome.
    Cancer. 2020;126:2811-2820.
    PubMed     Abstract available

    May 2020
  9. LAI JS, Beaumont JL, Kupst MJ, Peipert JD, et al
    Symptom burden trajectories experienced by patients with brain tumors.
    Cancer. 2020 May 6. doi: 10.1002/cncr.32879.
    PubMed     Abstract available

    April 2020
  10. PRESS RH, Shafer SL, Jiang R, Buchwald ZS, et al
    Optimal timing of chemoradiotherapy after surgical resection of glioblastoma: Stratification by validated prognostic classification.
    Cancer. 2020 Apr 28. doi: 10.1002/cncr.32797.
    PubMed     Abstract available

  11. LIN J, Bytnar JA, Theeler BJ, McGlynn KA, et al
    Survival among patients with glioma in the US Military Health System: A comparison with patients in the Surveillance, Epidemiology, and End Results Program.
    Cancer. 2020 Apr 14. doi: 10.1002/cncr.32884.
    PubMed     Abstract available

    March 2020
  12. RAUSCH CR, Jabbour EJ, Kantarjian HM, Kadia TM, et al
    Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management.
    Cancer. 2020;126:1152-1160.

  13. KONG L, Wu J, Gao J, Qiu X, et al
    Particle radiation therapy in the management of malignant glioma: Early experience at the Shanghai Proton and Heavy Ion Center.
    Cancer. 2020 Mar 13. doi: 10.1002/cncr.32828.
    PubMed     Abstract available

  14. LEE EQ, Zhang P, Wen PY, Gerstner ER, et al
    NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma.
    Cancer. 2020 Mar 10. doi: 10.1002/cncr.32811.
    PubMed     Abstract available

  15. POPP I, Rau S, Hintz M, Schneider J, et al
    Hippocampus-avoidance whole-brain radiation therapy with a simultaneous integrated boost for multiple brain metastases.
    Cancer. 2020 Mar 6. doi: 10.1002/cncr.32787.
    PubMed     Abstract available

  16. AKBARI H, Rathore S, Bakas S, Nasrallah MP, et al
    Histopathology-validated machine learning radiographic biomarker for noninvasive discrimination between true progression and pseudo-progression in glioblastoma.
    Cancer. 2020 Mar 4. doi: 10.1002/cncr.32790.
    PubMed     Abstract available

    February 2020
  17. DE FINE LICHT S, Maraldo MV, Specht L, Nielsen TT, et al
    Risk factors for cardiovascular disease in 5-year survivors of adolescent and young adult cancer: A Danish population-based cohort study.
    Cancer. 2020;126:659-669.
    PubMed     Abstract available

    January 2020
  18. MORAVAN MJ, Fecci PE, Anders CK, Clarke JM, et al
    Current multidisciplinary management of brain metastases.
    Cancer. 2020 Jan 23. doi: 10.1002/cncr.32714.
    PubMed     Abstract available

  19. SONG Y, Barry WT, Seah DS, Tung NM, et al
    Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
    Cancer. 2020;126:271-280.
    PubMed     Abstract available

    November 2019
  20. ZHANG H, Zhu H, Deng G, Zito CR, et al
    PLEKHA5 regulates tumor growth in metastatic melanoma.
    Cancer. 2019 Nov 26. doi: 10.1002/cncr.32611.
    PubMed     Abstract available

  21. KALRA M, Adra N, Hanna N, Abonour R, et al
    High-dose chemotherapy plus peripheral blood stem cell transplantation for patients with relapsed germ cell tumors and active brain metastases.
    Cancer. 2019 Nov 19. doi: 10.1002/cncr.32628.
    PubMed     Abstract available

    October 2019
  22. HOLBROOK K, Lutzky J, Davies MA, Davis JM, et al
    Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series.
    Cancer. 2019 Oct 28. doi: 10.1002/cncr.32547.
    PubMed     Abstract available

  23. PRINTZ C
    Some elderly survivors of 3 common cancers have an increased risk of brain metastases.
    Cancer. 2019;125:3286-3287.

    August 2019
  24. OFFIN M, Feldman D, Ni A, Myers ML, et al
    Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers.
    Cancer. 2019 Aug 30. doi: 10.1002/cncr.32461.
    PubMed     Abstract available

  25. LIN JJ, Gainor JF
    Time to tackle the blood-brain barrier in HER2-mutant lung cancer.
    Cancer. 2019 Aug 30. doi: 10.1002/cncr.32460.

  26. SCHVARTSMAN G, Ma J, Bassett RL Jr, Haydu LE, et al
    Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma.
    Cancer. 2019 Aug 9. doi: 10.1002/cncr.32454.
    PubMed     Abstract available

    July 2019
  27. JURATLI TA, Jones PS, Wang N, Subramanian M, et al
    Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations.
    Cancer. 2019 Jul 17. doi: 10.1002/cncr.32197.

  28. GALANIS E, Anderson SK, Twohy EL, Carrero XW, et al
    A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872.
    Cancer. 2019 Jul 10. doi: 10.1002/cncr.32340.
    PubMed     Abstract available

  29. RULLI E, Legramandi L, Salvati L, Mandala M, et al
    The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta-analysis.
    Cancer. 2019 Jul 9. doi: 10.1002/cncr.32375.
    PubMed     Abstract available

  30. WANG H, Ou Q, Li D, Qin T, et al
    Genes associated with increased brain metastasis risk in non-small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non-small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036).
    Cancer. 2019 Jul 9. doi: 10.1002/cncr.32372.
    PubMed     Abstract available

    June 2019
  31. BACK MF, Jayamanne D, Back E, Kastelan M, et al
    Reflecting on survivorship outcomes to aid initial decision making in patients treated for IDH-mutated anaplastic glioma.
    Cancer. 2019 Jun 28. doi: 10.1002/cncr.32352.
    PubMed     Abstract available

  32. RIS MD, Leisenring WM, Goodman P, Di C, et al
    Neuropsychological and socioeconomic outcomes in adult survivors of pediatric low-grade glioma.
    Cancer. 2019 Jun 24. doi: 10.1002/cncr.32186.
    PubMed     Abstract available

  33. COTE DJ, Ostrom QT, Gittleman H, Duncan KR, et al
    Glioma incidence and survival variations by county-level socioeconomic measures.
    Cancer. 2019 Jun 17. doi: 10.1002/cncr.32328.
    PubMed     Abstract available

  34. ZAPOTOCKY M, Beera K, Adamski J, Laperierre N, et al
    Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: Cure at a cost.
    Cancer. 2019;125:1867-1876.
    PubMed     Abstract available

    May 2019
  35. PRINTZ C
    First person profile: Michelle Monje, MD, PhD: Her research on how normal brain functions contribute to pediatric brain tumors may help physicians fight a lethal childhood cancer.
    Cancer. 2019;125:1397-1398.

    February 2019
  36. MARAKA S, Groves MD, Penas-Prado M
    Reply to Unexpectedly low rates of neuropsychiatric adverse effects associated with mefloquine repurposed for the treatment of glioblastoma.
    Cancer. 2019 Feb 1. doi: 10.1002/cncr.31960.

  37. NEVIN RL
    Unexpectedly low rates of neuropsychiatric adverse effects associated with mefloquine repurposed for the treatment of glioblastoma.
    Cancer. 2019 Feb 1. doi: 10.1002/cncr.31961.

    January 2019
  38. PRINTZ C
    Pediatric computed tomography scans: Weighing the risks and benefits: A new study suggests that computed tomography-related radiation may increase the risk of brain tumors, but the conversation, physicians say, is complex-and far from settled.
    Cancer. 2019;125:171-173.

  39. LIU APY, Hastings C, Wu S, Bass JK, et al
    Treatment burden and long-term health deficits of patients with low-grade gliomas or glioneuronal tumors diagnosed during the first year of life.
    Cancer. 2019 Jan 8. doi: 10.1002/cncr.31918.
    PubMed     Abstract available

    December 2018
    Mismatch repair in endometrioid endometrial cancer: Increasing our therapeutic proficiency by capitalizing on molecular deficiency.
    Cancer. 2018 Dec 18. doi: 10.1002/cncr.31902.

  41. BACKES FJ, Haag J, Cosgrove CM, Suarez A, et al
    Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker.
    Cancer. 2018 Dec 18. doi: 10.1002/cncr.31901.
    PubMed     Abstract available

  42. GEURTS M, van den Bent MJ
    On high-risk, low-grade glioma: What distinguishes high from low?
    Cancer. 2018 Dec 4. doi: 10.1002/cncr.31834.

    November 2018
  43. PRINTZ C
    Can a repurposed vaccine fight cancer?: Use of the poliovirus vaccine to target brain tumors draws interest.
    Cancer. 2018;124:4273-4274.

    October 2018
  44. MARAKA S, Groves MD, Mammoser AG, Melguizo-Gavilanes I, et al
    Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma.
    Cancer. 2018 Oct 25. doi: 10.1002/cncr.31811.
    PubMed     Abstract available

  45. YEH TC, Liang DC, Hou JY, Jaing TH, et al
    Treatment of childhood acute lymphoblastic leukemia with delayed first intrathecal therapy and omission of prophylactic cranial irradiation: Results of the TPOG-ALL-2002 study.
    Cancer. 2018 Oct 10. doi: 10.1002/cncr.31758.
    PubMed     Abstract available

    September 2018
  46. KUMAR R, Liu APY, Orr BA, Northcott PA, et al
    Advances in the classification of pediatric brain tumors through dna methylation profiling: from research tool to frontline diagnostic.
    Cancer. 2018 Sep 26. doi: 10.1002/cncr.31583.
    PubMed     Abstract available

    August 2018
  47. PRESS RH, Zhang C, Cassidy RJ, Ferris MJ, et al
    Targeted Sequencing and Intracranial Outcomes of Patients With Lung Adenocarcinoma Brain Metastases Treated With Radiotherapy.
    Cancer. 2018 Aug 18. doi: 10.1002/cncr.31589.
    PubMed     Abstract available

    June 2018
  48. KAMRAN SC, Goldberg SI, Kuhlthau KA, Lawell MP, et al
    Quality of life in patients with proton-treated pediatric medulloblastoma: Results of a prospective assessment with 5-year follow-up.
    Cancer. 2018 Jun 15. doi: 10.1002/cncr.31575.
    PubMed     Abstract available

    April 2018
  49. WICK W, Winkler F
    Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas.
    Cancer. 2018 Apr 26. doi: 10.1002/cncr.31371.

    March 2018
  50. UEMURA MI, French JT, Hess KR, Liu D, et al
    Development of CNS metastases and survival in patients with inflammatory breast cancer.
    Cancer. 2018 Mar 26. doi: 10.1002/cncr.31336.
    PubMed     Abstract available

  51. LEHRER S, Rheinstein PH, Rosenzweig KE
    Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma.
    Cancer. 2018 Mar 15. doi: 10.1002/cncr.31262.

  52. SLOOT S, Chen YA, Zhao X, Weber JL, et al
    Reply to Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma.
    Cancer. 2018 Mar 15. doi: 10.1002/cncr.31261.

  53. ZUREICK AH, Evans CL, Niemierko A, Grieco JA, et al
    Left hippocampal dosimetry correlates with visual and verbal memory outcomes in survivors of pediatric brain tumors.
    Cancer. 2018 Mar 2. doi: 10.1002/cncr.31143.
    PubMed     Abstract available

    January 2018
  54. WELLER M
    Where does O(6) -methylguanine DNA methyltransferase promoter methylation assessment place temozolomide in the future standards of care for glioblastoma?
    Cancer. 2018 Jan 30. doi: 10.1002/cncr.31244.

  55. SCHIFF D, Jaeckle KA, Anderson SK, Galanis E, et al
    Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572.
    Cancer. 2018 Jan 3. doi: 10.1002/cncr.31219.
    PubMed     Abstract available

  56. WANG N, Bertalan MS, Brastianos PK
    Leptomeningeal metastasis from systemic cancer: Review and update on management.
    Cancer. 2018;124:21-35.
    PubMed     Abstract available

    December 2017
  57. REARDON DA, Lassman AB, Schiff D, Yunus SA, et al
    Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma.
    Cancer. 2017 Dec 19. doi: 10.1002/cncr.31172.
    PubMed     Abstract available

  58. JHAVERI J, Liu Y, Chowdhary M, Buchwald ZS, et al
    Is less more? Comparing chemotherapy alone with chemotherapy and radiation for high-risk grade 2 glioma: An analysis of the National Cancer Data Base.
    Cancer. 2017 Dec 4. doi: 10.1002/cncr.31158.
    PubMed     Abstract available

    November 2017
  59. GEORGAKIS MK, Papathoma P, Ryzhov A, Zivkovic-Perisic S, et al
    Malignant central nervous system tumors among adolescents and young adults (15-39 years old) in 14 Southern-Eastern European registries and the US Surveillance, Epidemiology, and End Results program: Mortality and survival patterns.
    Cancer. 2017;123:4458-4471.
    PubMed     Abstract available

  60. RYDZEWSKI NR, Lesniak MS, Chandler JP, Kalapurakal JA, et al
    Gross total resection and adjuvant radiotherapy most significant predictors of improved survival in patients with atypical meningioma.
    Cancer. 2017 Nov 13. doi: 10.1002/cncr.31088.
    PubMed     Abstract available

    October 2017
  61. SHEN CJ, Hu C, Ladra MM, Narang AK, et al
    Socioeconomic factors affect the selection of proton radiation therapy for children.
    Cancer. 2017;123:4048-4056.
    PubMed     Abstract available

  62. SLOOT S, Chen YA, Zhao X, Weber JL, et al
    Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.
    Cancer. 2017 Oct 12. doi: 10.1002/cncr.30946.
    PubMed     Abstract available

  63. MILLER JJ, Shih HA, Andronesi OC, Cahill DP, et al
    Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.
    Cancer. 2017 Oct 5. doi: 10.1002/cncr.31039.
    PubMed     Abstract available

    September 2017
  64. HAN CH, Batchelor TT
    Diagnosis and management of primary central nervous system lymphoma.
    Cancer. 2017 Sep 26. doi: 10.1002/cncr.30965.
    PubMed     Abstract available

  65. ARBOUR KC, Kris MG, Riely GJ, Ni A, et al
    Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases.
    Cancer. 2017 Sep 21. doi: 10.1002/cncr.30990.
    PubMed     Abstract available

  66. Wearable medical device improves survival for glioblastoma patients.
    Cancer. 2017;123:3433.

  67. BENZ LS, Wrensch MR, Schildkraut JM, Bondy ML, et al
    Quality of life after surgery for intracranial meningioma.
    Cancer. 2017 Sep 13. doi: 10.1002/cncr.30975.
    PubMed     Abstract available

  68. DIAO K, Sun Y, Yoo SK, Yu C, et al
    Safety-net versus private hospital setting for brain metastasis patients treated with radiosurgery alone: Disparities in follow-up care and outcomes.
    Cancer. 2017 Sep 13. doi: 10.1002/cncr.30984.
    PubMed     Abstract available

  69. BLUM MURPHY M, Xiao L, Patel VR, Maru DM, et al
    Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience.
    Cancer. 2017 Sep 8. doi: 10.1002/cncr.30953.
    PubMed     Abstract available

    July 2017
  70. WAHL M, Chang SM, Phillips JJ, Molinaro AM, et al
    Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas.
    Cancer. 2017 Jul 31. doi: 10.1002/cncr.30909.
    PubMed     Abstract available

  71. FIELD KM, Phal PM, Fitt G, Goh C, et al
    The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: Results from a prospective clinical trial (CABARET).
    Cancer. 2017 Jul 5. doi: 10.1002/cncr.30838.
    PubMed     Abstract available

  72. SATO M, Gunther JR, Mahajan A, Jo E, et al
    Progression-free survival of children with localized ependymoma treated with intensity-modulated radiation therapy or proton-beam radiation therapy.
    Cancer. 2017;123:2570-2578.
    PubMed     Abstract available

  73. ALVAREZ E, Keegan T, Johnston EE, Haile R, et al
    Adolescent and young adult oncology patients: Disparities in access to specialized cancer centers.
    Cancer. 2017;123:2516-2523.
    PubMed     Abstract available

    June 2017
  74. WESTPHAL D, Glitza Oliva IC, Niessner H
    Molecular insights into melanoma brain metastases.
    Cancer. 2017;123.
    PubMed     Abstract available

  75. JOHNSON DB, Sullivan RJ, Menzies AM
    Immune checkpoint inhibitors in challenging populations.
    Cancer. 2017;123:1904-1911.
    PubMed     Abstract available

    May 2017
  76. LEHMANN V, Tuinman MA, Keim MC, Winning AM, et al
    Psychosexual development and satisfaction in long-term survivors of childhood cancer: Neurotoxic treatment intensity as a risk indicator.
    Cancer. 2017;123:1869-1876.
    PubMed     Abstract available

    April 2017
  77. AMSBAUGH MJ, Yusuf MB, Gaskins J, Burton EC, et al
    Patterns of care and predictors of adjuvant therapies in elderly patients with glioblastoma: An analysis of the National Cancer Database.
    Cancer. 2017 Apr 27. doi: 10.1002/cncr.30730.
    PubMed     Abstract available

  78. DEFILIPP Z, Li S, El-Jawahri A, Armand P, et al
    High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.
    Cancer. 2017 Apr 3. doi: 10.1002/cncr.30695.
    PubMed     Abstract available

  79. KAWAMURA J, Kamoshida S, Shimakata T, Hayashi Y, et al
    Filter paper-assisted cell transfer (FaCT) technique: A novel cell-sampling technique for intraoperative diagnosis of central nervous system tumors.
    Cancer. 2017;125:277-282.
    PubMed     Abstract available

  80. YANEZ ML, Miller JJ, Batchelor TT
    Diagnosis and treatment of epidural metastases.
    Cancer. 2017;123:1106-1114.
    PubMed     Abstract available

    February 2017
  81. FISCHER-VALUCK BW, Chen I, Srivastava AJ, Floberg JM, et al
    Assessment of the treatment approach and survival outcomes in a modern cohort of patients with atypical teratoid rhabdoid tumors using the National Cancer Database.
    Cancer. 2017;123:682-687.
    PubMed     Abstract available

  82. LANIER JC, Abrams AN
    Posterior fossa syndrome: Review of the behavioral and emotional aspects in pediatric cancer patients.
    Cancer. 2017;123:551-559.
    PubMed     Abstract available

  83. MILLER JA, Kotecha R, Ahluwalia MS, Mohammadi AM, et al
    Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
    Cancer. 2017 Feb 13. doi: 10.1002/cncr.30616.
    PubMed     Abstract available

  84. SANDLER KA, Shaverdian N, Cook RR, Kishan AU, et al
    Treatment trends for patients with brain metastases: Does practice reflect the data?
    Cancer. 2017 Feb 8. doi: 10.1002/cncr.30607.
    PubMed     Abstract available

  85. ACQUAYE AA, Vera E, Gilbert MR, Armstrong TS, et al
    Clinical presentation and outcomes for adult ependymoma patients.
    Cancer. 2017;123:494-501.
    PubMed     Abstract available

    January 2017
  86. PRINTZ C
    Device rapidly measures cell growth and can help determine drug resistance in cancer.
    Cancer. 2017;123:10-11.

    November 2016
  87. DUNN-PIRIO AM, Vlahovic G
    Immunotherapy approaches in the treatment of malignant brain tumors.
    Cancer. 2016 Nov 22. doi: 10.1002/cncr.30371.
    PubMed     Abstract available

    October 2016
  88. BOELE FW, Given CW, Given BA, Donovan HS, et al
    Family caregivers' level of mastery predicts survival of patients with glioblastoma: A preliminary report.
    Cancer. 2016 Oct 27. doi: 10.1002/cncr.30428.
    PubMed     Abstract available

  89. Erratum: Pallini R, Ricci-Vitiani L, Montano N, Mollinari C, Biffoni M, Cenci T, Pierconti F, Martini M, De Maria R and Larocca LM. Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis. Cancer. 2011;117:162-17
    Cancer. 2016;122:3090.

    September 2016
  90. CALDARELLA A, Barchielli A
    Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009.
    Cancer. 2016 Sep 13. doi: 10.1002/cncr.30341.

  91. GRAMATZKI D, Weller M
    Reply to glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009.
    Cancer. 2016 Sep 13. doi: 10.1002/cncr.30340.

    August 2016
  92. SHOUSHTARI AN, Munhoz RR, Kuk D, Ott PA, et al
    The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
    Cancer. 2016 Aug 17. doi: 10.1002/cncr.30259.
    PubMed     Abstract available

    June 2016
  93. DASENBROCK HH, Devine CA, Liu KX, Gormley WB, et al
    Thrombocytopenia and craniotomy for tumor: A National Surgical Quality Improvement Program analysis.
    Cancer. 2016;122:1708-17.
    PubMed     Abstract available

    May 2016
  94. VERMA V, Mishra MV, Mehta MP
    A systematic review of the cost and cost-effectiveness studies of proton radiotherapy.
    Cancer. 2016;122:1483-501.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Neoplasms of the CNS is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.